Loading
The first dedicated immunotherapy trial in NUT carcinoma, asking whether a PD-1 antibody can do anything in a cancer that chemotherapy rarely controls.
Case reports have described occasional responses of NUT carcinoma to checkpoint inhibitors despite its low mutation burden. This Northwestern University pilot gives cemiplimab to fifteen patients with metastatic or unresectable disease and measures safety and clinical activity. It is recruiting.
Shares NUT carcinoma (midline carcinoma with NUTM1 rearrangement) and the tag owner-request.
Shares NUT carcinoma (midline carcinoma with NUTM1 rearrangement) and the tag owner-request.
Shares NUT carcinoma (midline carcinoma with NUTM1 rearrangement) and the tag owner-request.
Shares Immune checkpoint inhibitors and the tag owner-request.
Shares Cemiplimab, Immune checkpoint inhibitors.
Shares Cemiplimab, Immune checkpoint inhibitors.
Shares Cemiplimab, Immune checkpoint inhibitors.
Shares Cemiplimab, Immune checkpoint inhibitors.